Compare HAFN & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HAFN | LEGN |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.6B |
| IPO Year | 2020 | 2020 |
| Metric | HAFN | LEGN |
|---|---|---|
| Price | $8.83 | $15.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 14 |
| Target Price | $11.50 | ★ $40.93 |
| AVG Volume (30 Days) | 2.0M | ★ 2.5M |
| Earning Date | 11-18-2026 | 11-10-2026 |
| Dividend Yield | ★ 12.37% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $38.78 |
| Revenue Next Year | N/A | $17.61 |
| P/E Ratio | $11.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.17 | $15.73 |
| 52 Week High | $11.12 | $37.50 |
| Indicator | HAFN | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.53 | 31.52 |
| Support Level | $8.54 | N/A |
| Resistance Level | $9.06 | $19.92 |
| Average True Range (ATR) | 0.36 | 1.39 |
| MACD | -0.12 | -0.73 |
| Stochastic Oscillator | 5.97 | 0.49 |
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk. Company manages it's business through the following reporting segments: LR2 tankers, LR1 tankers, MR tankers, Handy tankers.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.